DVT Nuances: The Essentials
From December 2019, Anxious AdolescentsRegardless of your clinical setting, DVT’s are a common entity that we need to be very comfortable working up and treating. And though on the surface the workup and Tx is seemingly straightforward...the truth is there are some nuances and special cases that aren’t completely intuitive...Mizuho …
13min 31Salim Rezaie, MD and Mizuho Morrison, DO
DVT Nuances: Advanced Care
From December 2019, Anxious AdolescentsRegardless of your clinical setting, DVT’s are a common entity that we need to be very comfortable working up and treating. And though on the surface the workup and Tx is seemingly straightforward...the truth is there are some nuances and special cases that aren’t completely intuitive...Mizuho …
20min 8Mizuho Morrison, DO and Salim Rezaie, MD
Benign Ethnic Neutropenia
From November 2019, Just Say No To TeratogensWhen Neda learned that one of her patients might have benign ethnic neutropenia, she knew she needed to do some research. Here she and Aisha discuss the diagnosis and management of this interesting condition. •
15min 4Aisha Lofters, MD and Neda Frayha, MD
Intro: Porphyrias in Primary Care
From October 2019, Oh, Porphyria!One of our listeners asked, “what’s the deal with porphyria? I don’t get it.” We bet this listener is not alone. Paul and Neda kick off the October episode with a breakdown of acute intermittent porphyria and porphyria cutanea tarda and how we may spot them in primary care. And yes, there is a King …
15min 8Neda Frayha, MD and Paul Simmons, MD
Hemophilias with Dr. Tom DeLoughery, Part 1
From October 2019, Oh, Porphyria!Hematology Rounds are back with our beloved hematologist, Dr. Tom DeLoughery. Here he sits down with our own Matt DeClerck to talk about how to diagnose and treat hemophilias in our day to day practices. • 6.2.6
20min 22Tom Deloughery, MD and Matthieu DeClerck, MD
Hemophilias with Dr. Tom DeLoughery, Part 2
From October 2019, Oh, Porphyria!Hematology Rounds are back with our beloved hematologist, Dr. Tom DeLoughery. Here he sits down with our own Matt DeClerck to talk about how to diagnose and treat hemophilias in our day to day practices. • 6.2.6
14min 48Tom Deloughery, MD and Matthieu DeClerck, MD
Polycythemia Vera - Part 2
From May 2019, This Mailbag is About to Rupture!Polycythemia vera is a relatively rare myeloproliferative disorder characterized by increased RBC production. In this segment, our own Matt DeClerck interviews Hematology guru Dr. Tom Deloughery on the in’s and out’s of PV. Clinical suspicion for PV should occur in any patient with elevated RBC …
10min 34Tom Deloughery, MD and Matthieu DeClerck, MD
Polycythemia Vera - Part 1
From May 2019, This Mailbag is About to Rupture!Polycythemia vera is a relatively rare myeloproliferative disorder characterized by increased RBC production. In this segment, our own Matt DeClerck interviews Hematology guru Dr. Tom Deloughery on the in’s and out’s of PV. Clinical suspicion for PV should occur in any patient with elevated RBC …
21min 1Tom Deloughery, MD and Matthieu DeClerck, MD
Eosinophilia
From February 2019, Into Thin HairWhat to do when you notice incidental eosinophilia in a patient? In this segment, Tom walks Neda through a fascinating case of peripheral eosinophilia, what it means, and how to work it up in the most strategic, effective way.
15min 18Tom Robertson, MD and Neda Frayha, MD
DOAC Reversal
From February 2019, Into Thin HairContinuing the recent discussion between Matt DeClerck and Dr. Tom Deloughery on the direct oral anticoagulants (DOACs), this month we bring you a segment on reversing these DOACs with Matt, Neda, and Dr. Tarlan Hedayati. What are the agents currently on the market, including the newest kid on the …
20min 52Tarlan Hedayati, MD, Neda Frayha, MD, and Matthieu DeClerck, MD
Sickle Cell Emergencies
From December 2018, Clots and OCP's1 in 5000 Americans has sickle cell disease, and these patients are at high risk for a variety of complications. Mizuho sits down with Jessica Osterman and Katie Harter to discuss sickle cell disease, pain crisis and emergencies.
21min 48Katherine Harter, MD, Jess Osterman, MD, and Mizuho Morrison, DO
Clots and OCPs
From December 2018, Clots and OCP'sOur listeners are always asking for more Hematology content. They are also always asking for more Ob/Gyn content! In this segment, Neda and Rob address the two together with a few cases featuring both hypercoagulability and contraception.
10min 23Rob Orman, MD and Neda Frayha, MD
Superficial Thrombophlebitis
From November 2018, Those Clots are So SuperficialWhen PC RAP listener Lisa wrote us that she’s observed different clinicians manage superficial thrombophlebitis in lots of different ways, from doing absolutely nothing to serial ultrasound to anticoagulation, our own Rob Orman couldn’t wait to put his love of hematology to use. In this segment, he …
11min 25Rob Orman, MD and Neda Frayha, MD
Anticoagulation with the DOACs
From October 2018, My Pancreas is Necrosing!It’s time for Hematology Rounds with Dr. Tom DeLoughery! In this segment, he and our own Matt DeClerck review the indications for and potential benefits and pitfalls of the direct oral anticoagulants (DOACs).
31min 9Tom Deloughery, MD and Matthieu DeClerck, MD
Paper Chase #4 | Ferrous Sulfate vs Iron Polysaccharide Complex in Kids with IDA
From April 2018, Will You Be My Facebook Friend?Ferrous sulfate led to a greater increase in hemoglobin concentration at 12 weeks and higher rates of resolution of iron-deficiency anemia compared with iron polysaccharide complex. Good old, tried-and-true ferrous sulfate for the win.
5min 34Andrew Buelt, DO and Joe Weatherly, DO
DOACs for VTE in Cancer - Tom DeLoughery for the Win!
From March 2018, DOACs for VTE in Cancer - Tom DeLoughery for the Win!Tom DeLoughery predicted a new practice pattern in an earlier PC RAP and he turned out to be totally right, so we’re proud to say “you heard it here first.”
5min 28Andrew Buelt, DO
Cancer & Thrombosis
From February 2018, The Tragically Sore HipTom Deloughery shares his wisdom on all things cancer and thrombosis. First, he reviews why patients with cancer are more likely to have clots, then reviews some aspects of thrombosis that are unique to this population. Lastly, he discusses treatment standards, nuances and controversies.
18min 54Tom Deloughery, MD and Matthieu DeClerck, MD
The COMPASS Trial
From February 2018, The Tragically Sore HipThis branch of the COMPASS trial examined 3 anticoagulation strategies in patients with “stable atherosclerotic disease”: rivaroxaban 5mg BID, ASA 100mg od + placebo BID, ASA 100 BID + rivaroxaban 2.5 mg BID. Casey’s analysis focused on the ASA groups, not the NOAC alone group. He concludes that …
13min 36Casey Parker, MD
Hematology Rounds - Thrombocytopenia
From November 2017, Lytes and BitesDr. Deloughery reviews his approach to the incidental thrombocytopenia. He reviews the differential in sick and well appearing pt. He describes the major causes of thrombocytopenia and suggests a stepwise approach to evaluation.
14min 29Tom Deloughery, MD and Heidi James, MD
The Tools of Satan: IVC Filters
From October 2017, It's Bloody Halloween!More and more research is showing that inferior vena cava filters may just be the Tools of Satan. At least Hematologist Tom Deloughery thinks. In this chapter, Tom and Heidi discuss a recent article on the diminishing role of IVC filters in thrombosis management.
16min 30Tom Deloughery, MD and Heidi James, MD
‹ PreviousNext ›